Metaflumizone is a semicarbazone broad-spectrum insecticide developed by Nihon Nohyaku with activity on Lepidoptera, Coleoptera, and certain Hemiptera.

Metaflumizone is chemically similar to pyrazoline sodium channel blocker insecticides (SCBIs) discovered at Philips-Duphar in the early 1970s, but is less dangerous to mammals than earlier compounds.

[3] Metaflumizone belongs to IRAC group 22B and works by blocking sodium channels in target insects, resulting in flaccid paralysis.

However, in a cross comparison with other veterinary flea control substances, Metaflumizone was not shown to result in a significant reduction in the number of engorged adult female Culex mosquitoes.

In 2011, Pfizer Animal Care decided to cease production of the drug based on findings which linked its use to an elevated incidence of the autoimmune disorder pemphigus foliaceus.